natgillin/translations-raw huggingface dataset:
The second study looked at whether Irbesartan Zentiva increased the time taken until the patients’ blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
V drugi študiji so proučevali, ali zdravilo Irbesartan Zentiva podaljša čas, v katerem se raven kreatinina (označevalca ledvičnega obolenja) v krvi bolnikov podvoji, čas do pojava potrebe po presaditvi ledvic ali dializi oziroma čas do nastopa smrti.
The second study looked at whether Karvea increased the time taken until the patients’ blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
V drugi študiji so preučevali, ali zdravilo Karvea podaljša čas, v katerem se raven kreatinina (označevalca ledvičnega obolenja) v krvi bolnikov podvoji, čas do pojava potrebe po presaditvi ledvic ali dializi oziroma čas do nastopa smrti.
The second study showed a similar effect of Orencia on symptoms of rheumatoid arthritis, as well as improved physical function and a reduced rate of joint damage after a year of treatment.
V drugi študiji je bil po enem letu zdravljenja opažen podoben učinek zdravila Orencia na simptome revmatoidnega artritisa, poleg tega pa sta bili opaženi izboljšana fizična funkcija in zmanjšana stopnja poškodb sklepov.
The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in paediatric patients (ages 6 months to 17 years) with invasive candidiasis, oesophageal candidiasis, and invasive aspergillosis (as salvage therapy).
Druga študija je bila prospektivna, odprta, neprimerjalna študija varnosti in učinkovitosti kaspofungina pri pediatričnih bolnikih (starih od 6 mesecev do 17 let) z invazivno kandidiazo, ezofagealno kandidiazo in invazivno aspergilozo (kot rešilno zdravljenje).
The second study was in 3,057 patients who had undergone a knee replacement.
Druga študija je bila izvedena pri 3 057 bolnikih, ki so jim operativno vstavili umetno koleno.
The second study, involving 749 adults, compared Xeplion with risperidone long-acting injection (taken with oral risperidone supplements) and looked at the change in the patients’ symptoms.
V drugi študiji, v kateri je sodelovalo 749 odraslih bolnikov, so zdravilo Xeplion primerjali z dolgo delujočo injekcijo risperidona (ki se jemlje s peroralnimi dodatki risperidona) in ugotavljali spremembe simptomov pri bolnikih.
The second trial utilised a dose of 300 mg/m2 as a 30 minute infusion in 63 patients with metastatic breast cancer.
Pri drugi raziskavi so uporabili odmerek 300 mg/m2 kot 30- minutno infuzijo pri 63 bolnikih z metastatskim rakom dojk.
The second ‘click’ means that the injection is finished and the needle has gone back into the pre-filled pen.
Drugi ‘klik’ pomeni, da je injiciranje končano in se je igla vrnila nazaj v napolnjeni injekcijski peresnik.
The secondary composite endpoint of recurrent VTE and all-cause mortality occurred in 138 subjects (3.4%) in the edoxaban group and 158 subjects (3.9%) in the warfarin group [HR (95% CI): 0.87 (0.70, 1.10)].
Sekundarni sestavljeni kriterij, ki sta ga sestavljala recidivni VTE in smrtnost ne glede na vzrok, so ugotovili pri 138 preiskovancih (3,4 %) v skupini z edoksabanom in 158 preiskovancih (3,9 %) v skupini z varfarinom [HR (95 % CI): 0,87 (0,70, 1,10)].
The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all cause mortality.
Sekundarni izid učinkovitosti je bil sestavljen iz ponovne GVT, nesmrtne PE in smrtnosti zaradi vseh vzrokov.
The secondary endpoint of complete resolution of heartburn, defined as no heartburn on the patient’s diary card for 7 consecutive days, was statistically significant at both week 1 (10.0% - 15.2% vs placebo 0.9% - 2.4%, p = 0.014, p<0.001) and week 2 (25.2% - 35.7% vs placebo 3.4% - 9.0%, p<0.001).
Sekundarni opazovani dogodek, popolno prenehanje zgage, opredeljen kot odsotnost zgage v bolnikovem dnevniku 7 zaporednih dni, je bil statistično pomemben po enem tednu (10,0–15,2 % v primerjavi s placebom 0,9–2,4 %, p = 0,014, p < 0,001) in po 2 tednih (25,2–35,7 % v primerjavi s placebom 3,4–9,0 %, p < 0,001).
The secondary endpoints in the table above reached statistical significance in the whole population.) The secondary endpoints of combined all cause death or life-threatening experience, all cause death, or all cause hospitalisation did not reach statistical significance in the whole population.
Sekundarni opazovani dogodki, navedeni v zgornji tabeli, so v celotni populaciji dosegli statistično značilnost.) Sekundarni opazovani dogodki – kombinacija smrtnih izidov ali življenje ogrožajočih dogodkov iz katerega koli vzroka, smrtni izidi iz katerega koli vzroka ali sprejemi v bolnišnico iz katerega koli vzroka v celotni populaciji niso dosegli statistične značilnosti.
The secondary endpoints were evaluation of overall objective response rate (ORR), disease control rate (DCR) defined as, partial response (PR) or complete response (CR) or stable disease (SD) lasting at least 24 weeks, duration of response (DOR), time to worsening of pain based on Brief Pain Inventory (BPI) worst pain scale, and overall survival (OS).
Sekundarni opazovani dogodki so bili celotni delež objektivnega odziva (ORR – objective response rate), delež obvladanja bolezni (DCR – disease control rate) opredeljen kot delni odziv (PR – partial response) ali popolni odziv (CR – complete response) ali stabilna bolezen (SD – stable disease) v trajanju vsaj 24 mesecev, trajanje odziva (DOR – duration of response), čas do poslabšanja bolečin na podlagi lestvice najhujše bolečine vprašalnika BPI (brief pain inventory) in celokupno preživetje (OS – overall survival).
The secondary endpoints were progression-free survival in the ITT population and overall survival (OS), overall response rate (ORR), and duration of response in the primary efficacy population and ITT population.
Sekundarni opazovani dogodki so bili preživetje brez napredovanja v populaciji ZNZ, celokupno preživetje (OS – overall survival), celokupni delež odziva (ORR – overall response rate) in trajanje odziva v primarni populaciji učinkovitosti in v populaciji ZNZ.
The secondary measures of efficacy included global assessments of improvement by the examiner, Activities of Daily Living (ADL) subscale scores when OFF and UPDRS motor while ON.
Sekundarna merila učinkovitosti so vključevala ocenjevalčevo globalno oceno izboljšanja, dosežene točke na podlestvici Vprašalnika vsakodnevnih aktivnosti (Activities of Daily Living -ADL) v času OFF in motorični UPDRS v času ON.
The secondary objectives included complete response (CR) and overall response (CR or partial response) rates using the 1996 NCIWG criteria, the duration of response, time to alternative treatment and safety of the two treatment arms.
Sekundarni cilji vključujejo popolni odziv (CR) in celokupni odziv (CR ali delni odziv) po kriterijih 1996 NCIWG za trajanje odziva, časa do alternativnega zdravljenja in varnost obeh načinov zdravljenja.
The secretory pathway appears not to include known acidic or basic transport systems involved in the excretion of other active substances.(see section 4.5).
Poti izločanja ne vključujejo znanih kislinskih ali bazičnih transportnih sistemov, ki sodelujejo pri izločanju drugih zdravilnih učinkovin.
The section 4.4 of the summary of product characteristics and the relevant sections of the package leaflet were updated.
Poglavje 4.4 povzetka glavnih značilnosti zdravila in ustrezni deli navodila za uporabo so bili posodobljeni.
The seizure does not stop within 10 minutes
epileptični napad ne mine v 10 minutah;
The SELECT study was a multicentre, randomised, double-blind, placebo-controlled trial that was conducted in 392 patients with radioiodine-refractory differentiated thyroid cancer with independent, centrally reviewed, radiographic evidence of disease progression within 12 months (+1 month window) prior to enrollment.
Študija SELECT je bila multicentrično, randomizirano, dvojno slepo, s placebom kontrolirano preskušanje, opravljeno pri 392 bolnikih z diferenciranim rakom ščitnice, odpornim proti radioaktivnemu jodu, z neodvisno ugotovljenimi, centralno pregledovanimi radiografskimi znaki napredovanja bolezni v 12 mesecih (+ 1-mesečno okno) pred vključitvijo.
The selection of 0.2 mg/kg dose (infused over 40 minutes) for the registration clinical studies was intended to temporarily saturate the ability of the mannose-6- phosphate receptors to internalize the agalsidase alfa in the liver and allow distribution of enzyme to other relevant organ tissues.
Izbira odmerka 0,2 mg/kg (40-minutna infuzija) za klinične študije za pridobitev dovoljenja za promet z zdravilom je bila namenjena začasnemu nasičenju sposobnosti manoza-6-fosfatnih receptorjev za internalizacijo agalzidaze alfa v jetrih in omogočanju porazdelitve encima v druga pomembna organska tkiva.
The selection of formulation is based on individual characteristics of the patient.
Farmacevtsko obliko izberemo glede na specifične lastnosti posameznega bolnika.
The selection of formulation is based on individual characteristics of the patient.
Farmacevtsko obliko zdravila je treba izbrati glede na individualne lastnosti posameznega bolnika (glejte poglavje 4.1).
The selection of formulation is based on individual characteristics of the patient..
Farmacevtsko obliko izberemo glede na specifične lastnosti posameznega bolnika.
The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear.
Selektivno delovanje difosfonatov na kost temelji na njihovi veliki afiniteti do mineralizirane kosti, vendar natančen molekulski mehanizem zavrtja aktivnosti osteoklastov še ni jasen.
The selective antagonism of the angiotensin-II (AT1 ) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.
Selektivni antagonistični učinek na receptorje angiotenzina II (AT1 ) povzroči povečanje plazemske ravni renina in angiotenzina II, in zmanjšanje plazemske koncentracije aldosterona.
The selective serotonin reuptake inhibitor (SSRI) paroxetine is metabolized primarily by CYP2D6 and is also a potent CYP2D6 inhibitor.
Selektivni zaviralec ponovnega privzema serotonina (SSRI), paroksetin, se primarno presnavlja z encimom CYP2D6 in je prav tako močan zaviralec encima CYP2D6.
The selective toxicity of afoxolaner between insect/acarines and mammals may be inferred by the differential sensitivity of the insect/acarines’ GABA receptors versus mammalian receptors.
Sklepa se, da je selektivna toksičnost afoksolanera drugačna pri insektih/pršicah in sesalcih zaradi razlike v občutljivosti GABA receptorjev.
The selective toxicity of afoxolaner between insects, acarines and mammals may be inferred by the differential sensitivity of the insects and acarines’ GABA receptors versus mammalian GABA receptors.
Sklepa se, da je selektivna toksičnost učinkovine afoksolaner drugačna pri insektih/pršicah in sesalcih zaradi razlike v občutljivosti GABA receptorjev.
The sensitivity ranged from 60.6% to 63.4% and specificity from 88.6% to 91.4% when the possible DLB patients were included as DLB patients.
V primeru, da so bili bolniki z možno DLB demenco vključeni v skupino bolnikov z DLB demenco, pa je bila senzitivnost v mejah med 60,6% do 63,4%, specifičnost pa med 88,6% do 91,4%.
The separate pharmaceutical forms of efavirenz, emtricitabine and tenofovir disoproxil fumarate were used to determine the pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil fumarate, administered separately in HIV infected patients.
Za določanje farmakokinetičnih lastnosti efavirenza, emtricitabina in dizoproksiltenofovirijevega fumarata so bile uporabljene ločene farmacevtske oblike efavirenza, emtricitabina in dizoproksiltenofovirijevega fumarata, ki so bile pri bolnikih, okuženih z virusom HIV, uporabljene posebej.
The separation between the treatment arms was achieved by improvement in lung function in the pemetrexed/cisplatin arm and deterioration of lung function over time in the control arm.
Razlikovanje med vejama zdravljenja je bilo doseženo z izboljšanjem delovanja pljuč v veji zdravljenja s pemetreksedom /cisplatinom in poslabšanjem pljučnega delovanja s časom v kontrolni veji preskušanja.
The sequential administration of Nimenrix one month after a DTaP-HBV-IPV/Hib vaccine resulted in lower GMTs for antibody against groups A, C and W-135.
Z zaporedno uporabo cepiva Nimenrix en mesec po cepivu DTaP-HBV-IPV/Hib so bile dosežene nižje GMT protiteles proti skupinam A, C in W-135.
The serious adverse reactions observed more frequently (≥5%) with lenalidomide in combination with low dose dexamethasone (Rd and Rd18) than with melphalan, prednisone and thalidomide (MPT) were:
Resna neželena učinka, ki so ju opazili pogosteje (≥5 %) pri lenalidomidu v kombinaciji z deksametazonom v majhnem odmerku (Rd in Rd18) kot pri melfalanu, prednizonu in talidomidu (MPT), sta bila:
The serious adverse reactions observed more frequently (≥5%) with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance (MPR+R) or melphalan, prednisone and lenalidomide followed by placebo (MPR+p) than melphalan, prednisone and placebo followed by placebo (MPp+p) were:
Resna neželena učinka, ki so ju opazili pogosteje (≥5 %) pri melfalanu, prednizonu in lenalidomidu, ki jim je sledil vzdrževalni odmerek lenalidomida (MPR+R), ali pri melfalanu, prednizonu in lenalidomidu, ki jim je sledil placebo (MPR+p), kot pri melfalanu, prednizonu in placebu, ki jim je sledil placebo (MPp+p), sta bila:
The serious adverse reactions observed more frequently in Study MCL-002 (with a difference of at least 2 percentage points) in the lenalidomide arm compared with the control arm were:
Resni neželeni učinki, ki so jih v glavni študiji MCL-002 opažali pogosteje (z razliko vsaj 2 odstotnih točk) v skupini z lenalidomidom kot v kontrolni skupini, so bili:
The seroprotection rate against hepatitis B after the administration of Twinrix Adult was 92% and 56% at 7 and 48 months respectively, versus 80% and 43% after the GlaxoSmithKline Biologicals monovalent 20µg hepatitis B vaccine, and 71% and 31% after another licensed monovalent 10µg hepatitis B vaccine.
Stopnja serumske zaščite proti hepatitisu B po dajanju cepiva Twinrix za odrasle je bila 92 % po 7 mesecih in 56 % po 48 mesecih, po dajanju monovalentnega 20 µg cepiva proti hepatitisu B izdelovalca GlaxoSmithKline Biologicals pa 80 in 43 % (po 7 in po 48 mesecih) ter 71 in 31 % po dajanju nekega drugega monovalentnega 10 µg cepiva proti hepatitisu B z dovoljenjem za promet.
The seroprotection rate and seroconversion rate measured by HI assay and the seroconversion factor expressed as geometric mean ratio of HI for anti-HA antibody to H1N1 after administration of one and two 7.5 µg doses of Focetria was evaluated in 70 children and adolescents (9-17 years), 60 children (3-8 years), 58 children (12-35 months) and 49 infants (6-11 months).
Stopnji serozaščite in serokonverzije, izmerjeni z metodo HI, in faktor serokonverzije, izražen kot geometrijska srednja vrednost razmerja HI za protitelo proti HA in H1N1, so po dajanju enega in dveh 7,5 µg odmerkov zdravila Focetria ocenili pri 70 otrocih in mladostnikih (9–17 let), 60 otrocih (3–8 let), 58 otrocih (12–35 mesecev) in 49 dojenčkih (6–11 mesecev).
The seroprotection rate and seroconversion rate measured by HI assay and the seroconversion factor expressed as geometric mean ratios of HI for anti-HA antibody to H1N1 after administration of one and two 7.5 µg doses of Focetria was evaluated in 70 children and adolescents (9-17 years), 60 children (3-8 years), 58 children (12-35 months) and 49 infants (6-11 months).
Stopnji serozaščite in serokonverzije, izmerjeni z metodo HI, in faktor serokonverzije, izražen kot geometrijska srednja vrednost razmerja HI za protitelo proti HA in H1N1, so po dajanju enega in dveh 7,5 µg odmerkov zdravila Focetria ocenili pri 70 otrocih in mladostnikih (9–17 let), 60 otrocih (3–8 let), 58 otrocih (12–35 mesecev) in 49 dojenčkih (6–11 mesecev).
The seroprotection rate and seroconversion rate measured by HI assay and the seroconversion factor expressed as geometric mean ratios of HI for anti-HA antibody to H1N1 after administration of one and two7.5 µg doses of Focetria was evaluated in 70 children and adolescents (9-17 years), 60 children (3-8 years), 58 children (12-35 months) and 49 infants (6-11 months).
Stopnji serozaščite in serokonverzije, izmerjeni z metodo HI, in faktor serokonverzije, izražen kot geometrijska srednja vrednost razmerja HI za protitelo proti HA in H1N1, so po dajanju enega in dveh odmerkov zdravila Focetria po 7,5 µg ocenili pri 70 otrocih in mladostnikih (9–17 let), 60 otrocih (3– 8 let), 58 otrocih (12–35 mesecev) in 49 dojenčkih (6–11 mesecev).
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H1N1v in children aged 12-35 months by HI assay after administration of 7.5 µg of Focetria were as follows:
Stopnja serološke zaščite*, stopnja serološke konverzije* in faktor serološke konverzije** izmerjeni s testom HI za HA protitelesa H1N1v, po dajanju 7,5 µg cepiva Focetria pri otrocih, starih
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H1N1v in children and adolescents aged 9-17 years by HI assay after administration of 7.5 µg of Focetria were as follows:
Stopnja serološke zaščite*, stopnja serološke konverzije* in faktor serološke konverzije** izmerjeni s testom HI za HA protitelesa H1N1v, po dajanju 7,5 µg cepiva Focetria pri otrocih in mladostnikih, starih od 9-17 let:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in two clinical studies were as follows:
Stopnja serozaščite*, delež serokonverzije* in faktor serokonverzije** za protitelo proti HA na H5N1 A/Vietnam/1194/2004 pri preiskovancih, starejših od 60 let (omejeno število preiskovancev je bilo starejših od 70 let), izmerjeni s testom SRH in ocenjeni v dveh kliničnih študijah, so bili, kot sledi:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by Single Radial Haemolysis (SRH) assay was as follows:
Stopnja serozaščite*, delež serokonverzije* in faktor serokonverzije** za protitelo proti HA na H5N1 A/Vietnam/1194/2004 pri odraslih, izmerjeni s testom enkratne radialne hemolize (SRH – single radial haemolysis), so bili, kot sledi:
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 measured by SRH assays were as follows:
Stopnja serozaščite*, delež serokonverzije* in faktor serokonverzije** za protitelo proti HA na H5N1 A/Vietnam/1194/2004, izmerjeno s testom SRH, so bili, kot sledi:
The seroprotection rate, booster seroconversion rate and booster factor against A/Indonesia/5/2005 21 days after booster vaccination was 100%, 99.7% and 123.8%, respectively.
Delež serološke zaščite proti A/Indonesia/5/2005 21. dni po obnovitvenem cepljenju je bil 100 %, delež serokonverzije po obnovitvenem cepljenju 99,7 % in faktor obnovitve 123,8 %.
The seroprotection rate, booster seroconversion rate and booster factor against A/Indonesia/5/2005 21 days after booster vaccination was 100%, 99.7% and 123.8, respectively.
Delež serološke zaščite proti A/Indonesia/5/2005 21. dni po obnovitvenem cepljenju je bil 100 %, delež serokonverzije po obnovitvenem cepljenju 99,7 % in faktor obnovitve 123,8.
The seroprotection rate, the seroconversion rate and the seroconversion factor, using HI method, were as follows:
Delež serozaščite, delež serokonverzije in faktor serokonverzije po metodi HI so kot sledi:
The seroprotection rates for anti-HBs (10 mlU/ml) observed with the 6, 10, 14 week schedule was lower as shown in the table below, but is unlikely to be clinically relevant due to the small sample size:
Odstotek serozaščite s proti-HBs (( 10 i.e./ml) opažen pri shemi 6., 10., 14. teden je bil nižji od navedenega v preglednici v nadaljevanju, vendar pa je zaradi majhne velikosti vzorca malo verjetno, da bi to imelo klinični pomen:
The seroprotection rates were 16.3% and 4.7% at months 12 and 24, respectively.
Deleži serološke zaščite so bili 12. mesec 16,3 % in 24. mesec 4,7 %.
The serum adjusted EC90 value in 43 primary HIV-1 clinical isolates was 0.57 (0.06 – 10.7) ng/mL without significant changes between different subtypes tested.
Za serum prilagojena vrednost EC90 v 43 primarno HIV-1 kliničnih izolatih je bila 0,57 (0,06–10,7) ng/ml, brez bistvenih sprememb med različnimi testiranimi podvrstami.
The serum IGF-1 was normalised at the end of the study (week 12) in 9.7%, 38.5%, 75% and 82% of subjects treated with placebo, 10 mg/day, 15 mg/day or 20 mg/day pegvisomant respectively.
IGF-I v serumu je bil na koncu študije (12. teden) normalen pri 9,7 % preiskovancev, ki so dobivali placebo, med prejemniki pegvisomanta pa pri 38,5 % tistih, ki so ga dobivali 10 mg/dan, pri 75 % tistih, ki so ga dobivali 15 mg/dan, in pri 82 % tistih, ki so ga dobivali 20 mg/dan.
The severe hypoglycaemia event incidences were 2.4% and 3.4%, and rates were 0.05 and
Pojavnost dogodkov hude hipoglikemije je znašala 2,4 % oziroma 3,4 %, stopnje pa 0,05 oziroma 0,06 dogodkov/bolnika/leto.
The severe RV gastro-enteritis cases were due to RV strains G1P[8], G2P[4], G3P[8] and G9P[8].
Primere hudega RV gastroenteritisa so povzročili sevi RV G1P[8], G2P[4], G3P[8] in G9P[8].
The severity of adverse events of DepoCyte may be increased when DepoCyte is given in combination with other chemotherapeutic agents.
Resnost neželenih učinkov zdravila DepoCyte se lahko poveča, če se zdravilo DepoCyte daje v kombinaciji z drugimi kemoterapevtiki.
The severity of adverse events of docetaxel may be increased when docetaxel is given in combination with other chemotherapeutic agents.
Izrazitost neželenih učinkov docetaksel se lahko poveča, če se zdravilo daje v kombinaciji z drugimi kemoterapevtiki.
The severity of adverse events of Docetaxel may be increased when Docetaxel is given in combination with other chemotherapeutic agents.
Izrazitost neželenih učinkov docetaksela se lahko poveča, če dobivate docetaksel v kombinaciji z drugimi kemoterapevtiki.
The severity of adverse events of Docetaxel Winthrop may be increased when Docetaxel Winthrop is given in combination with other chemotherapeutic agents.
Izrazitost neželenih učinkov zdravila Docetaxel Winthrop se lahko poveča, če dobivate zdravilo Docetaxel Winthrop v kombinaciji z drugimi kemoterapevtiki.
The severity of the local and systemic reactions was mainly from grade 1 (mild) to grade 2 (moderate).
Lokalne in sistemske reakcije so bile v splošnem 1. stopnje (blage) do 2. stopnje (zmerne).
the severity of your disease
resnosti vaše bolezni,
the severity of your haemophilia
alvarleika dreyrasýkinnar
the severity of your haemophilia
topnja hemofilije
the severity of your haemophilia
topnja motnje strjevanja krvi
the severity of your illness,
resnosti vaše bolezni,
The shaded areas in this diagram show the places where you can give yourself the injection.
Osenčena polja na tej sliki kažejo mesta, kamor si lahko injicirate zdravilo.
The shape of the vial means that a very small amount of the medicine will be left behind in the vial.
Zaradi oblike viale zelo majhna količina zdravila ostane v njej.
The shelf-life of the reconstituted suspension is 2 months
Rok uporabnosti pripravljene suspenzije je 2 meseca
The shelf-life of the reconstituted suspension is two months.
Rok uporabnosti pripravljene suspenzije je 2 meseca.
The shell of the capsule consists of gelatin, titanium dioxide, Brilliant Blue FCF, Erythrosine, and Orange Yellow S (E110).
Ovojnica kapsule sestoji iz želatine, titanovega dioksida, briljantno modrega FCF barvila, eritrozina in oranžno rumenega S barvila (E110).